To evaluate the oncological outcomes, specifically metastasis-free survival (MFS) and overall survival (OS), of salvage radiotherapy (sRT) patients after radical prostatectomy, focusing on the impact of PSA levels at initiation.
Key Findings:
Median PSA level at sRT initiation was 0.33 ng/ml, indicating a trend towards lower levels in early intervention.
69% of patients received early sRT (PSA < 0.5 ng/ml), suggesting a preference for timely treatment.
Early sRT patients had a median PSA of 0.24 ng/ml compared to 0.89 ng/ml in the standard sRT group, highlighting the impact of timing on treatment outcomes.
Higher rates of high-risk features (pT3–4, Gleason score 8–10, pN1) were observed in the study population, emphasizing the need for targeted interventions.
Interpretation:
The study suggests that initiating sRT at lower PSA levels may improve MFS, particularly in high-risk patients, aligning with recent findings that advocate for early intervention and potentially influencing clinical guidelines.
Limitations:
Retrospective design may introduce selection bias, potentially affecting the reliability of the findings.
Single-center study limits generalizability of findings, necessitating multi-center validation.
Further validation needed for PSA thresholds to establish definitive clinical guidelines.
Conclusion:
Early initiation of sRT at lower PSA levels may enhance metastasis-free survival in patients post-radical prostatectomy, particularly those with high-risk features, warranting further investigation.
by Mike Wenzel, Benedikt Lauer, Kathrin Burdenski, Nikolaos Tselis, Claus Rödel, Christian Brandts, Marit Ahrens, Jens Köllermann, Markus Graefen, Clara Humke, Carolin Siech, Benedikt Hoeh, Felix K. H. Chun, Philipp Mandel
